Monitoring of glycemic control is the cornerstone of managementfor insulin-dependent diabetes mellitus, HbA1C levels in hemodialysispatients can be influenced by starting or stopping EPO treatment, andHbA1C levels can decrease or increase according to the increase ordecrease of hematocrite caused by changing the EPO dosage,respectively.Our study included 40 patients on regular hemodialysis who areEPO naïve: 30 patients diabetic and 10 patients were not diabetics’controls. HBA1c was measured before and after a 3 month EPO therapyby column chromatography, fasting blood sugar, hemoglobin,electrolytes, albumin and renal functions were measured. HBA1cdecreased significantly with negative correlation with hemoglobin, butindependent of FBS and other variables .The study concluded thatHBA1c was not reliable marker for glycemic control in diabetichemodialysis patient on EPO therapy.